» Articles » PMID: 32014948

Efficacy of Staging Laparoscopy for Pancreatic Cancer

Overview
Journal Anticancer Res
Specialty Oncology
Date 2020 Feb 5
PMID 32014948
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Preoperative evaluation of resectability of pancreatic cancer (PC) is difficult, so that staging laparoscopy (SL) has come to be used for detecting occult metastases. We aimed to evaluate the prognostic impact of SL in comparison with exploratory laparotomy (EL) in unresectable PC.

Patients And Methods: Between 2010 and 2016, 57 patients with PC underwent SL after conventional tumor staging. Patient characteristics, operative findings and survival rates were compared between SL and EL group.

Results: Twenty patients (35%) were identified as having unresectable factors in SL group. In contrast, laparotomy showed unresectable factors in 8 patients who did not receive preoperative SL (EL group). The time between the surgery to the induction of chemotherapy was significantly shorter in the SL group (mean=6 days, range=2-17) than in the EL group (mean=10 days, range=6-15). There was no significant difference in overall survival between the two groups; however, EL was associated with shorter survival in the early postoperative period.

Conclusion: SL was associated with a shorter time interval to chemotherapy and lead to the prevention of unnecessary laparotomy.

Citing Articles

Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology.

Igarashi T, Fukasawa M, Watanabe T, Kimura N, Itoh A, Tanaka H Ann Gastroenterol Surg. 2024; 8(1):124-132.

PMID: 38250680 PMC: 10797817. DOI: 10.1002/ags3.12719.


Surgical management of pancreatic ductal adenocarcinoma: a narrative review.

Sarfaty E, Khajoueinejad N, Zewde M, Yu A, Cohen N Transl Gastroenterol Hepatol. 2023; 8:39.

PMID: 38021357 PMC: 10643215. DOI: 10.21037/tgh-23-27.


Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study.

Shindo Y, Tokumitsu Y, Matsui H, Nakajima M, Kimura Y, Iida M In Vivo. 2023; 37(6):2704-2709.

PMID: 37905607 PMC: 10621419. DOI: 10.21873/invivo.13380.


Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study.

Turner M, Cox K, Neel N, Amirfakhri S, Nishino H, Clary B J Pers Med. 2023; 13(5).

PMID: 37241027 PMC: 10221372. DOI: 10.3390/jpm13050857.


Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.

Fiore M, Coppola A, Petrianni G, Trecca P, DErcole G, Cimini P J Gastrointest Oncol. 2023; 14(2):1114-1130.

PMID: 37201095 PMC: 10186502. DOI: 10.21037/jgo-22-1034.